Outcome of surgery for ileojejunal neuroendocrine tumors

Surgery Today

Volumn 43, Issue 10, 2013, Pages 1168-1174

  Habbe, Nils ^a   Fendrich, Volker ^a   Heverhagen, Anna ^a   Ramaswamy, Annette ^a   Bartsch, Detlef K ^a  

^a UNIVERSITY HOSPITAL MARBURG   (Germany)

Author keywords

Carcinoid; Liver metastases; NET; Neuroendocrine tumor; SI NET; Small bowel carcinoid

Indexed keywords

ADULT; AGED; ARTICLE; CANCER ADJUVANT THERAPY; CANCER LOCALIZATION; CANCER PROGNOSIS; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; CHEMOEMBOLIZATION; CLINICAL FEATURE; CONTROLLED STUDY; DISEASE SPECIFIC SURVIVAL; DISTANT METASTASIS; FEMALE; HUMAN; ILEOJEJUNAL NEUROENDOCRINE TUMOR; LIVER METASTASIS; LYMPH NODE DISSECTION; MAJOR CLINICAL STUDY; MALE; NEUROENDOCRINE TUMOR; OUTCOME ASSESSMENT; OVERALL SURVIVAL; RETROSPECTIVE STUDY; SMALL INTESTINE TUMOR; SURVIVAL RATE; TUMOR VOLUME;

ADULT; AGED; AGED, 80 AND OVER; COMBINED MODALITY THERAPY; DIGESTIVE SYSTEM SURGICAL PROCEDURES; FEMALE; HUMANS; ILEAL NEOPLASMS; JEJUNAL NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM METASTASIS; NEOPLASM STAGING; NEUROENDOCRINE TUMORS; PALLIATIVE CARE; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 84884906168     PISSN: 09411291     EISSN: 14362813     Source Type: Journal    
DOI: 10.1007/s00595-012-0408-1     Document Type: Article

References (24)

1. Yao JC, Hassan M, Phan A, Dagohoy C, Leary C, Mares JE, et al. One hundred years after "carcinoid": epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States. J Clin Oncol. 2008;26(18):3063-72.
2. Ellis L, Shale MJ, Coleman MP. Carcinoid tumors of the gastrointestinal tract: trends in incidence in England since 1971. Am J Gastroenterol. 2010;105(12):2563-9.
3. Modlin IM, Champaneria MC, Chan AK, Kidd M. A three-decade analysis of 3,911 small intestinal neuroendocrine tumors: the rapid pace of no progress. Am J Gastroenterol. 2007;102(7):1464-73.
4. Rivadeneira DE, Tuckson WB, Naab T. Increased incidence of second primary malignancy in patients with carcinoid tumors: case report and literature review. J Natl Med Assoc. 1996;88:310-2.
5. Brune M, Gerdes B, Koller M, Rothmund M. Neuroendocrine tumors of the gastrointestinal tract (NETGI) and second primary malignancies-which is dominant? Dtsch Med Wochenschr. 2003;128(46):2413-7.
6. Soga J. Carcinoids of the small intestine: a statistical evaluation of 1102 cases collected from the literature. J Exp Clin Cancer Res 1997;16:353-63.
7. Rinke A, Müller HH, Schade-Brittinger C, Klose KJ, Barth P, Wied M, PROMID Study Group, et al. Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID Study Group. J Clin Oncol. 2009;27(28):4656-63.
8. Yantiss RK, Odze RD, Farraye FA, Rosenberg AE. Solitary versus multiple carcinoid tumors of the ileum: a clinical and pathologic review of 68 cases. Am J Surg Pathol. 2003;27(6):811-7.
9. Burke AP, Thomas RM, Elsayed AM, Sobin LH. Carcinoids of the jejunum and ileum: an immunohistochemical and clinicopathologic study of 167 cases. Cancer. 1997;79(6):1086-93.
10. Modlin IM, Sandor A. An analysis of 8305 cases of carcinoid tumors. Cancer. 1997;79:813-29.
11. Godwin JD II. Carcinoid tumors: an analysis of 2,837 cases. Cancer. 1975;36:560-9.
12. Modlin IM, Gustafsson BI, Pavel M, Svejda B, Lawrence B, Kidd M. A nomogram to assess small-intestinal neuroendocrine tumor ('carcinoid') survival. Neuroendocrinology. 2010;92(3):143-57.
13. Plöckinger U, Rindi G, Arnold R, Eriksson B, Krenning EP, de Herder WW, European Neuroendocrine Tumor Society, et al. Guidelines for the diagnosis and treatment of neuroendocrine gastrointestinal tumors. A consensus statement on behalf of the European Neuroendocrine Tumor Society (ENETS). Neuroendocrinology. 2004;80(6):394-424.
14. Klöppel G, Couvelard A, Perren A, Komminoth P, McNicol AM, Nilsson O et al. European Neuroendocrine Tumor Society. ENETS consensus guidelines for the standards of care in neuroendocrine tumors: towards a standardized approach to the diagnosis of gastroenteropancreatic neuroendocrine tumors and their prognostic stratification. Neuroendocrinology;2009;90 (2162-6).
15. Akerström G, Hellman P, Hessman O, Osmak L. Management of midgut carcinoids. J Surg Oncol. 2005;89(3):161-9.
16. Rindi G, Arnold R, Bosman FT, et al. Nomenclature and classification of neuroendocrine neoplasms of the digestive system. In: Bosman TF, Carneiro F, Hruban RH, Theise ND, editors. WHO classification of tumours of the digestive system. 4th ed. Lyon: International Agency for Research on cancer (IARC), 2010. p. 13.
17. Cunningham JL, Díaz de Ståhl T, Sjöblom T, Westin G, Dumanski JP, Janson ET. Common pathogenetic mechanism involving human chromosome 18 in familial and sporadic ileal carcinoid tumors. Genes Chromosom Cancer. 2011;50(2):82-94.
18. Modlin IM, Latich I, Zikusoka M, Kidd M, Eick G, Chan AK. Gastrointestinal carcinoids: the evolution of diagnostic strategies. J Clin Gastroenterol. 2006;40(7):572-82.
19. Modlin IM, Kidd M, Latich I, Zikusoka MN, Shapiro MD. Current status of gastrointestinal carcinoids. Gastroenterology. 2005;128(6):1717-51.
20. Landerholm K, Zar N, Andersson RE, Falkmer SE, Järhult J. Survival and prognostic factors in small bowel carcinoid tumour. Br J Surg. 2011;98(11):1617-24.
21. Maggard MA, O′Connell JB, Ko CY. Updated population-based review of carcinoid tumors. Ann Surg. 2004;240(1):117-22.
22. Norlén O, Stålberg P, Oberg K, Eriksson J, Hedberg J, Hessman O. Long-term results of surgery for small intestinal neuroendocrine tumors at a tertiary referral center. World J Surg. 2012;36(6):1419-31.
23. Kimura W, Tezuka K, Hirai I. Surgical management of pancreatic neuroendocrine tumors. Surg Today. 2011;41(10):1332-43.
24. Pavel ME, Hainsworth JD, Baudin E, Peeters M, Hörsch D, Winkler RE, RADIANT-2 Study Group, et al. Everolimus plus octreotide long-acting repeatable for the treatment of advanced neuroendocrine tumours associated with carcinoid syndrome (RADIANT-2): a randomised, placebo-controlled, phase 3 study. Lancet. 2011;378(9808):2005-12.